FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158867438> ?p ?o ?g. }

• W2158867438 endingPage "e21" @default.
• W2158867438 startingPage "e13" @default.
• W2158867438 abstract "Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to disrupt HIV-1 latency and the safety of this strategy.In this phase 1/2 clinical trial, we included aviraemic adults with HIV treated at Aarhus University Hospital, Denmark. Participants received oral panobinostat (20 mg) three times per week every other week for 8 weeks while maintaining combination antiretroviral therapy. The primary outcome was change from baseline of cell-associated unspliced HIV RNA. Secondary endpoints were safety, plasma HIV RNA, total and integrated HIV DNA, infectious units per million CD4 T cells, and time to viral rebound during an optional analytical treatment interruption of antiretroviral therapy. This trial is registered with ClinicalTrial.gov, number NCT01680094.We enrolled 15 patients. The level of cell-associated unspliced HIV RNA increased significantly at all timepoints when patients were taking panobinostat (p < 0·0001). The median maximum increase in cell-associated unspliced HIV RNA during panobinostat treatment was 3·5-fold (range 2·1-14·4). Panobinostat induced plasma viraemia with an odds ratio of 10·5 (95% CI 2·2-50·3; p = 0·0002) compared with baseline. We recorded a transient decrease in total HIV DNA, but no cohort-wide reduction in total HIV DNA, integrated HIV DNA, or infectious units per million. Nine patients participated in the analytical treatment interruption, median time to viral rebound was 17 days (range 14-56). Panobinostat was well tolerated. 45 adverse events were reported, but only 16 (all grade 1) were presumed related to panobinostat.Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication. However, panobinostat did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir.The Danish Council for Strategic Research and Aarhus University." @default.
• W2158867438 created "2016-06-24" @default.
• W2158867438 creator A5005530326 @default.
• W2158867438 creator A5019085141 @default.
• W2158867438 creator A5019482614 @default.
• W2158867438 creator A5028234430 @default.
• W2158867438 creator A5039283842 @default.
• W2158867438 creator A5040598120 @default.
• W2158867438 creator A5049151623 @default.
• W2158867438 creator A5050504640 @default.
• W2158867438 creator A5054912665 @default.
• W2158867438 creator A5062645957 @default.
• W2158867438 creator A5074394409 @default.
• W2158867438 creator A5080911867 @default.
• W2158867438 creator A5082310426 @default.
• W2158867438 creator A5086897371 @default.
• W2158867438 date "2014-10-01" @default.
• W2158867438 modified "2023-10-17" @default.
• W2158867438 title "Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial" @default.
• W2158867438 cites W1590436404 @default.
• W2158867438 cites W1603334203 @default.
• W2158867438 cites W1965266980 @default.
• W2158867438 cites W1981563918 @default.
• W2158867438 cites W2004995106 @default.
• W2158867438 cites W2015983043 @default.
• W2158867438 cites W2022450093 @default.
• W2158867438 cites W2028919540 @default.
• W2158867438 cites W2030844138 @default.
• W2158867438 cites W2035947707 @default.
• W2158867438 cites W2037524921 @default.
• W2158867438 cites W2038598840 @default.
• W2158867438 cites W2051879794 @default.
• W2158867438 cites W2054061812 @default.
• W2158867438 cites W2055142955 @default.
• W2158867438 cites W2055796578 @default.
• W2158867438 cites W2060829964 @default.
• W2158867438 cites W2064743809 @default.
• W2158867438 cites W2075906228 @default.
• W2158867438 cites W2085384576 @default.
• W2158867438 cites W2106051882 @default.
• W2158867438 cites W2120014878 @default.
• W2158867438 cites W2125080468 @default.
• W2158867438 cites W2132626699 @default.
• W2158867438 cites W2139250164 @default.
• W2158867438 cites W2140187410 @default.
• W2158867438 cites W2145246179 @default.
• W2158867438 cites W2158013970 @default.
• W2158867438 cites W2163345503 @default.
• W2158867438 cites W2171991138 @default.
• W2158867438 doi "https://doi.org/10.1016/s2352-3018(14)70014-1" @default.
• W2158867438 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26423811" @default.
• W2158867438 hasPublicationYear "2014" @default.
• W2158867438 type Work @default.
• W2158867438 sameAs 2158867438 @default.
• W2158867438 citedByCount "512" @default.
• W2158867438 countsByYear W21588674382014 @default.
• W2158867438 countsByYear W21588674382015 @default.
• W2158867438 countsByYear W21588674382016 @default.
• W2158867438 countsByYear W21588674382017 @default.
• W2158867438 countsByYear W21588674382018 @default.
• W2158867438 countsByYear W21588674382019 @default.
• W2158867438 countsByYear W21588674382020 @default.
• W2158867438 countsByYear W21588674382021 @default.
• W2158867438 countsByYear W21588674382022 @default.
• W2158867438 countsByYear W21588674382023 @default.
• W2158867438 crossrefType "journal-article" @default.
• W2158867438 hasAuthorship W2158867438A5005530326 @default.
• W2158867438 hasAuthorship W2158867438A5019085141 @default.
• W2158867438 hasAuthorship W2158867438A5019482614 @default.
• W2158867438 hasAuthorship W2158867438A5028234430 @default.
• W2158867438 hasAuthorship W2158867438A5039283842 @default.
• W2158867438 hasAuthorship W2158867438A5040598120 @default.
• W2158867438 hasAuthorship W2158867438A5049151623 @default.
• W2158867438 hasAuthorship W2158867438A5050504640 @default.
• W2158867438 hasAuthorship W2158867438A5054912665 @default.
• W2158867438 hasAuthorship W2158867438A5062645957 @default.
• W2158867438 hasAuthorship W2158867438A5074394409 @default.
• W2158867438 hasAuthorship W2158867438A5080911867 @default.
• W2158867438 hasAuthorship W2158867438A5082310426 @default.
• W2158867438 hasAuthorship W2158867438A5086897371 @default.
• W2158867438 hasConcept C126322002 @default.
• W2158867438 hasConcept C142462285 @default.
• W2158867438 hasConcept C143998085 @default.
• W2158867438 hasConcept C156957248 @default.
• W2158867438 hasConcept C159047783 @default.
• W2158867438 hasConcept C197934379 @default.
• W2158867438 hasConcept C203014093 @default.
• W2158867438 hasConcept C203092338 @default.
• W2158867438 hasConcept C2776202225 @default.
• W2158867438 hasConcept C2778305200 @default.
• W2158867438 hasConcept C2780225316 @default.
• W2158867438 hasConcept C3013748606 @default.
• W2158867438 hasConcept C535046627 @default.
• W2158867438 hasConcept C54355233 @default.
• W2158867438 hasConcept C552990157 @default.
• W2158867438 hasConcept C64927066 @default.
• W2158867438 hasConcept C71924100 @default.
• W2158867438 hasConcept C86803240 @default.

• next